Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Akero Therapeutics is conducting a Phase 3 study titled ‘A Phase ...

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of MedicineThree presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant ...

Explore Akero Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for AKRO. The bear market induced by the Federal Reserve’s monetary tightening ...

Get the annual and quarterly balance sheet of Akero Therapeutics, Inc. (AKRO) including details of assets, liabilities and shareholders' equity.

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The ...

Investor Contact: Christina Tartaglia 212.362.1200 [email protected] Media Contact: Peg Rusconi 617.910.6217 [email protected] Source: Akero Therapeutics Inc. 2024 GlobeNewswire, Inc.

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor ...

Akero Therapeutics (AKRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the ...

In a recent move at Akero Therapeutics, Inc. (NASDAQ: AKRO), Chief Development Officer Yale Catriona sold shares worth more than $150,000. The transaction, which took place on September 20, 2024, ...

Akero Therapeutics (NASDAQ: AKRO) stock is soaring 120% and is one of today’s top trending tickers on sites like Yahoo Finance. The rally was sparked by the company’s release of positive data ...